LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding ...

and be considered for first-line treatment with an EGFR tyrosine kinase inhibitor if a mutation is identified.

Lazertinib is an oral, highly selective, third-generation EGFR tyrosine kinase inhibitor that can penetrate the brain, and amivantamab is a bispecific antibody targeting EGFR and mesenchymal ...

Considering taking supplements to treat egfr inhibitor induced acneiform rash? Below is a list of common natural remedies used to treat or reduce the symptoms of egfr inhibitor induced acneiform rash.

This includes olafertinib, a third-generation EGFR inhibitor (similar in principle ... and they have enough drugs to support the conduct of a phase 1 study. As of their latest quarterly filing ...

Successful treatment of severe lung cancer caused by third-generation EGFR-TKI resistance due to EGFR genotype conversion with afatinib plus anlotinib. Complete response of recurrent perihilar ...

an eGFR of 35-90 mL/min/1.73m 2, blood pressure <140/90 mm Hg, a urine protein-creatinine ratio ≥0.8 g/g or urine protein ≥1 g/day, and stable and optimized RAS inhibitor therapy with an ACE ...

safe and convenient treatment for patients with EGFR-mutated lung cancer across stages and lines of treatment." Susan Galbraith, Executive Vice President, Oncology Hematology R&D, AstraZeneca ...

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed ...

Preclinical studies have demonstrated IDE275's (GSK959) potential as a best-in-class WRN inhibitor, inducing single-agent tumor regressions in MSI-H patient-derived xenograft (PDX) and cell line ...